FDA Rejects Lilly’s Eczema Treatment Over Third-Party Manufacturing Issues
BioSpace
OCTOBER 1, 2023
Eli Lilly’s Biologic License Application for its monoclonal antibody lebrikizumab was denied by the regulator after issues were found at a third-party contract manufacturing organization.
Let's personalize your content